SCM
HAE icon

SG Capital Management’s Haemonetics HAE Stock Holding History

SG Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-906,892
Closed -$56.1M – 82
2025
Q2 		$67.7M Buy
906,892
+187,460
+26% +$12.4M 4.68% 4
2025
Q1 		$45.7M Sell
719,432
-159,372
-18% -$10.8M 4.21% 8
2024
Q4 		$68.6M Buy
878,804
+235,365
+37% +$18.9M 6.63% 3
2024
Q3 		$51.7M Buy
643,439
+461,611
+254% +$37.3M 6.48% 3
2024
Q2 		$15M Buy
+181,828
New +$16M 2.35% 11
2023
Q2 		– Sell
-59,082
Closed -$4.89M – 63
2023
Q1 		$4.89M Buy
59,082
+42,184
+250% +$3.41M 1.67% 24
2022
Q4 		$1.33M Buy
+16,898
New +$1.36M 0.74% 36

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG Capital Management's HAE Position: Q3 2025 in Review

SG Capital Management sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 906,892 shares — an estimated $56.1M sold.

SG Capital Management first reported a position in HAE in Q4 2022 and held it in 7 quarters. The position peaked at $68.6M in Q4 2024. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • SG Capital Management reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
  • SG Capital Management sold 906,892 Haemonetics shares in Q3 2025, an estimated $56.1M.
  • SG Capital Management first reported a position in Haemonetics in Q4 2022 and held it in 7 quarters.
  • SG Capital Management's Haemonetics position peaked at $68.6M in Q4 2024.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on SG Capital Management's 13F filing for Q3 2025, filed 7 Nov 2025.